[{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"e4540d59-4ee0-4d85-b168-8b3f90bd2231","acronym":"","url":"https://clinicaltrials.gov/study/NCT06317662","created_at":"2024-03-19T13:40:49.211Z","updated_at":"2025-02-25T17:39:56.997Z","phase":"Phase 2","brief_title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","source_id_and_acronym":"NCT06317662","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • KMT2A • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • KMT2A • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 04/26/2025","start_date":" 04/26/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-01-29"},{"id":"babb040a-8e58-46a5-a8a3-a326e81d8c49","acronym":"MORAb-202-G000-201","url":"https://clinicaltrials.gov/study/NCT04300556","created_at":"2021-01-18T20:51:39.021Z","updated_at":"2025-02-25T14:29:08.502Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","source_id_and_acronym":"NCT04300556 - MORAb-202-G000-201","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • BRAF • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRAF • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-12-09"},{"id":"93d233c8-d3b1-4a92-8fd5-b306320c34dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586999","created_at":"2021-01-18T17:38:33.204Z","updated_at":"2025-02-25T14:27:16.447Z","phase":"Phase 1/2","brief_title":"Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas","source_id_and_acronym":"NCT03586999","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 05/26/2021","primary_completion_date":" 05/26/2021","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2024-10-29"},{"id":"64151ea0-5e4f-4551-a71f-36af8cc5de9e","acronym":"IPATential150","url":"https://clinicaltrials.gov/study/NCT03072238","created_at":"2021-01-17T17:45:45.867Z","updated_at":"2024-07-02T16:34:37.052Z","phase":"Phase 3","brief_title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03072238 - IPATential150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • ipatasertib (RG7440) • prednisone • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 1101","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/16/2020","primary_completion_date":" 03/16/2020","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2024-06-07"},{"id":"6a4ac4b8-ac4e-46a2-bb00-4f42aa1f1efd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01920932","created_at":"2021-01-18T08:40:01.212Z","updated_at":"2024-07-02T16:35:11.441Z","phase":"Phase 2","brief_title":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","source_id_and_acronym":"NCT01920932","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 08/12/2013","start_date":" 08/12/2013","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-04-04"},{"id":"e0c2d374-1a6e-41df-afa3-7f62a12323d8","acronym":"GAZELLE","url":"https://clinicaltrials.gov/study/NCT03817853","created_at":"2021-01-18T18:51:45.970Z","updated_at":"2024-07-02T16:35:11.337Z","phase":"Phase 4","brief_title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","source_id_and_acronym":"NCT03817853 - GAZELLE","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • cyclophosphamide intravenous • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 02/26/2019","start_date":" 02/26/2019","primary_txt":" Primary completion: 08/04/2020","primary_completion_date":" 08/04/2020","study_txt":" Completion: 01/25/2023","study_completion_date":" 01/25/2023","last_update_posted":"2024-04-04"},{"id":"6aea670a-703a-4441-a9ff-cf2cf5b73ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479267","created_at":"2021-01-18T21:30:41.002Z","updated_at":"2024-07-02T16:35:13.759Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","source_id_and_acronym":"NCT04479267","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/21/2020","start_date":" 08/21/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-03-20"},{"id":"6d194b66-a36a-4049-9be1-f272a6096889","acronym":"","url":"https://clinicaltrials.gov/study/NCT03117751","created_at":"2021-01-18T15:21:39.440Z","updated_at":"2024-07-02T16:35:16.300Z","phase":"Phase 2/3","brief_title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT03117751","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BCL2 • CEP72","pipe":"","alterations":" ","tags":["BCL2 • CEP72"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • bortezomib • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • Zolinza (vorinostat) • clofarabine • idarubicin hydrochloride • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Erwinase (erwinia asparaginase) • Purixan (mercaptopurine oral suspension) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 790","initiation":"Initiation: 03/29/2017","start_date":" 03/29/2017","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-03-05"},{"id":"3bd3fd36-e779-4b4f-aebf-3c0ec0514bc0","acronym":"B-NHL 2013","url":"https://clinicaltrials.gov/study/NCT03206671","created_at":"2021-01-18T15:48:24.533Z","updated_at":"2024-07-02T16:35:26.683Z","phase":"Phase 3","brief_title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","source_id_and_acronym":"NCT03206671 - B-NHL 2013","lead_sponsor":"University Hospital Muenster","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • prednisolone • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 650","initiation":"Initiation: 08/03/2017","start_date":" 08/03/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-12-11"},{"id":"59ecbc03-e206-4ecd-8590-2fbff8a3633e","acronym":"REMoDL-A","url":"https://clinicaltrials.gov/study/NCT04546620","created_at":"2021-01-18T21:44:57.916Z","updated_at":"2025-02-25T14:59:21.575Z","phase":"Phase 2","brief_title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04546620 - REMoDL-A","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","biomarkers":" ALK • MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-22"},{"id":"89043144-7499-4a05-af55-7ccd22ef32aa","acronym":"ACCEPT","url":"https://clinicaltrials.gov/study/NCT03571308","created_at":"2021-01-18T17:34:25.953Z","updated_at":"2024-07-02T16:35:35.619Z","phase":"Phase 1/2","brief_title":"A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT03571308 - ACCEPT","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 06/02/2017","start_date":" 06/02/2017","primary_txt":" Primary completion: 01/02/2020","primary_completion_date":" 01/02/2020","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2023-09-27"},{"id":"93766317-3ff9-4f80-ade3-ee042661108f","acronym":"ARCHED","url":"https://clinicaltrials.gov/study/NCT05820841","created_at":"2023-04-20T14:03:42.227Z","updated_at":"2025-02-25T15:00:51.328Z","phase":"Phase 3","brief_title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05820841 - ARCHED","lead_sponsor":"Universität des Saarlandes","biomarkers":" ALK • BCL2 • CD20 • BCL6 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • CD20 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-08-31"},{"id":"8d92e145-1e5f-4e56-b472-cedf7cfc6b38","acronym":"COALITION","url":"https://clinicaltrials.gov/study/NCT04914741","created_at":"2021-06-07T16:53:40.225Z","updated_at":"2024-07-02T16:35:39.206Z","phase":"Phase 1/2","brief_title":"A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04914741 - COALITION","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-08-23"},{"id":"d44a7a8c-52c4-4900-873b-a2464b0c7ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003520","created_at":"2021-01-18T14:46:26.498Z","updated_at":"2024-07-02T16:35:47.443Z","phase":"Phase 2","brief_title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03003520","lead_sponsor":"Celgene","biomarkers":" PD-L1 • CD20 • CD8 • IFNG","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • cyclophosphamide intravenous • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 02/28/2017","start_date":" 02/28/2017","primary_txt":" Primary completion: 04/24/2022","primary_completion_date":" 04/24/2022","study_txt":" Completion: 04/24/2022","study_completion_date":" 04/24/2022","last_update_posted":"2023-05-22"},{"id":"db3fd885-d5b5-42fd-ac3d-e1b4841a432f","acronym":"Epi-RCHOP","url":"https://clinicaltrials.gov/study/NCT02889523","created_at":"2021-01-18T14:10:49.396Z","updated_at":"2024-07-02T16:35:53.084Z","phase":"Phase 1/2","brief_title":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","source_id_and_acronym":"NCT02889523 - Epi-RCHOP","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Tazverik (tazemetostat) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-03-17"},{"id":"94fe4903-a2c9-42e8-862b-770fa6d33088","acronym":"I-HEP","url":"https://clinicaltrials.gov/study/NCT04810156","created_at":"2021-03-22T11:52:24.698Z","updated_at":"2025-02-25T14:02:17.911Z","phase":"Phase 2","brief_title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","source_id_and_acronym":"NCT04810156 - I-HEP","lead_sponsor":"Inge Marie Svane","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prednisone • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/07/2025","primary_completion_date":" 04/07/2025","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2022-12-14"},{"id":"a6fd0405-fc77-45a8-8618-63d6afa0c28a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04797325","created_at":"2021-03-15T15:53:37.014Z","updated_at":"2024-07-02T16:36:05.376Z","phase":"Phase 2","brief_title":"Vedolizumab for Immune Mediated Colitis","source_id_and_acronym":"NCT04797325","lead_sponsor":"University of Copenhagen","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Entyvio (vedolizumab) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-08-17"},{"id":"8e4357a2-05d1-42e3-b2c8-065d6b7cd1f5","acronym":"INCA","url":"https://clinicaltrials.gov/study/NCT01679119","created_at":"2021-01-18T07:16:28.308Z","updated_at":"2024-07-02T16:36:10.326Z","phase":"Phase 2","brief_title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","source_id_and_acronym":"NCT01679119 - INCA","lead_sponsor":"University College, London","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • cyclophosphamide intravenous • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 129","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2022-05-18"},{"id":"cdf6c9e0-2e9e-4ffb-b0ae-b679fa7d891e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792256","created_at":"2021-01-18T18:44:58.864Z","updated_at":"2024-07-02T16:36:16.243Z","phase":"Phase 1","brief_title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","source_id_and_acronym":"NCT03792256","lead_sponsor":"Children's Oncology Group","biomarkers":" RB1 • CD8 • CDK4 • CDK6 • CD4 • CCND3","pipe":" | ","alterations":" RB1 expression • CDK6 expression • CDKN1B expression","tags":["RB1 • CD8 • CDK4 • CDK6 • CD4 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 expression • CDK6 expression • CDKN1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • cytarabine • doxorubicin hydrochloride • vincristine • prednisone • Oncaspar liquid (pegaspargase) • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-03-02"},{"id":"6c5c3d7e-a57a-4db8-87cd-ab4453447383","acronym":"","url":"https://clinicaltrials.gov/study/NCT01448096","created_at":"2021-01-18T06:00:33.455Z","updated_at":"2024-07-02T16:36:57.231Z","phase":"Phase 2","brief_title":"Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT01448096","lead_sponsor":"Chonbuk National University Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • cyclophosphamide intravenous • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 07/10/2019","primary_completion_date":" 07/10/2019","study_txt":" Completion: 07/10/2019","study_completion_date":" 07/10/2019","last_update_posted":"2019-08-07"},{"id":"eb20b8a5-3ed9-42db-92ae-f5d814060799","acronym":"Interfant06","url":"https://clinicaltrials.gov/study/NCT00550992","created_at":"2021-01-18T02:00:23.012Z","updated_at":"2024-07-02T16:36:57.586Z","phase":"","brief_title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","source_id_and_acronym":"NCT00550992 - Interfant06","lead_sponsor":"Dutch Childhood Oncology Group","biomarkers":" KMT2A • CD34","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD34 positive","tags":["KMT2A • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • vincristine • prednisone • daunorubicin • mitoxantrone • leucovorin calcium • melphalan • Oncaspar liquid (pegaspargase) • mercaptopurine • busulfan • thioguanine • cyclosporine • prednisolone"],"overall_status":"Unknown status","enrollment":" Enrollment 445","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2019-07-30"},{"id":"7cc3c8f2-92e9-4770-a7bb-202c9b406a6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01381874","created_at":"2021-01-18T05:40:01.403Z","updated_at":"2024-07-02T16:37:00.694Z","phase":"Phase 2","brief_title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy","source_id_and_acronym":"NCT01381874","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • letrozole • prednisone • anastrozole • exemestane • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 297","initiation":"Initiation: 08/24/2011","start_date":" 08/24/2011","primary_txt":" Primary completion: 07/28/2014","primary_completion_date":" 07/28/2014","study_txt":" Completion: 08/08/2018","study_completion_date":" 08/08/2018","last_update_posted":"2019-04-11"}]